BRPI9807076B8 - "uso de acetato de glatirâmero para a fabricação de medicamento para o tratamento de esclerose múltipla e composição farmacêutica" - Google Patents

"uso de acetato de glatirâmero para a fabricação de medicamento para o tratamento de esclerose múltipla e composição farmacêutica"

Info

Publication number
BRPI9807076B8
BRPI9807076B8 BRPI9807076A BR9807076A BRPI9807076B8 BR PI9807076 B8 BRPI9807076 B8 BR PI9807076B8 BR PI9807076 A BRPI9807076 A BR PI9807076A BR 9807076 A BR9807076 A BR 9807076A BR PI9807076 B8 BRPI9807076 B8 BR PI9807076B8
Authority
BR
Brazil
Prior art keywords
treatment
multiple sclerosis
medicine
manufacture
pharmaceutical composition
Prior art date
Application number
BRPI9807076A
Other languages
English (en)
Other versions
BR9807076B1 (pt
BR9807076A (pt
Inventor
Gilbert Adrian
Teitelbaum Dvora
Sela Michael
Linenberg Milka
Arnon Ruth
Riven Kreitman Rvka
Original Assignee
Yeda Reserach And Dev Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Reserach And Dev Co Ltd filed Critical Yeda Reserach And Dev Co Ltd
Publication of BR9807076A publication Critical patent/BR9807076A/pt
Publication of BR9807076B1 publication Critical patent/BR9807076B1/pt
Publication of BRPI9807076B8 publication Critical patent/BRPI9807076B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Abstract

''tratamento de esclerose múltipla mediante ingestão ou inalação de copolímero-1'' a presente invenção se refere ao tratamento de esclerose múltipla pela ingestão ou inalação de copolímero-1 e a composições farmacêuticas utilizáveis para esse tratamento.
BRPI9807076A 1997-01-10 1998-01-12 "uso de acetato de glatirâmero para a fabricação de medicamento para o tratamento de esclerose múltipla e composição farmacêutica" BRPI9807076B8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IL11998997A IL119989A0 (en) 1997-01-10 1997-01-10 Pharmaceutical compositions for oral treatment of multiple sclerosis
PCT/US1998/000375 WO1998030227A1 (en) 1997-01-10 1998-01-12 Treatment of multiple sclerosis through ingestion or inhalation of copolymer-1

Publications (3)

Publication Number Publication Date
BR9807076A BR9807076A (pt) 2000-05-02
BR9807076B1 BR9807076B1 (pt) 2013-10-29
BRPI9807076B8 true BRPI9807076B8 (pt) 2021-05-25

Family

ID=11069682

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI9807076A BRPI9807076B8 (pt) 1997-01-10 1998-01-12 "uso de acetato de glatirâmero para a fabricação de medicamento para o tratamento de esclerose múltipla e composição farmacêutica"

Country Status (19)

Country Link
EP (1) EP0975351B1 (pt)
JP (1) JP4216342B2 (pt)
KR (1) KR20000070058A (pt)
CN (1) CN100528222C (pt)
AT (1) ATE356608T1 (pt)
AU (1) AU737287B2 (pt)
BR (1) BRPI9807076B8 (pt)
CA (1) CA2277365C (pt)
CZ (1) CZ297983B6 (pt)
DE (1) DE69837324T2 (pt)
EA (1) EA003128B1 (pt)
HK (1) HK1025737A1 (pt)
HU (1) HU226612B1 (pt)
IL (2) IL119989A0 (pt)
NZ (1) NZ336690A (pt)
PL (1) PL193300B1 (pt)
SK (1) SK284029B6 (pt)
WO (1) WO1998030227A1 (pt)
ZA (1) ZA98214B (pt)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2527760T3 (es) 1998-07-23 2015-01-29 Yeda Research And Development Co., Ltd. Tratamiento de enfermedad de Crohn con copolímero 1 y polipéptidos
EP1098902A4 (en) 1998-07-23 2002-07-24 Yeda Res & Dev TREATMENT OF AUTOIMMUNE DISEASES BY COPOLYMER 1 AND SIMILAR COPOLYMERS AND PEPTIDES
IL140592A0 (en) * 1998-07-23 2002-02-10 Harvard College Synthetic peptides and methods of use for autoimmune disease therapies
US6800287B2 (en) 1998-09-25 2004-10-05 Yeda Research And Development Co., Ltd. Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use
DE60041365D1 (de) * 1999-06-04 2009-02-26 Vereniging Voor Christelijk Wetenschappelijk Onderwijs Verwendung von Riluzol zur Behandlung Multipler Sklerose
NZ515685A (en) * 1999-06-04 2002-12-20 Vereniging Voor Christelijk Wetenschappelijk Onderwijs Use of riluzole for the treatment of multiple sclerosis
ZA200206457B (en) 2000-02-18 2003-08-13 Yeda Res & Dev Oral, nasal and pulmonary dosage formulations of copolymer 1.
WO2001060392A1 (en) * 2000-02-18 2001-08-23 Yeda Research And Development Co., Ltd. At The Weizmann Institute Of Science Oral, nasal and pulmonary dosage formualtions of copolymer 1
EP1292279A4 (en) * 2000-06-05 2005-01-12 Teva Pharma USE OF GLATIRAMER ACETATE (COPOLYMER 1) FOR TREATING DISEASES OF THE CENTRAL NERVOUS SYSTEM
US20020077278A1 (en) 2000-06-05 2002-06-20 Yong V. Wee Use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders
WO2002076503A1 (en) 2000-06-20 2002-10-03 Mayo Foundation For Medical Education And Research Treatment of central nervous system diseases by antibodies against glatiramer acetate
PT1459065E (pt) 2001-12-04 2010-10-11 Teva Pharma Processos para a medição da potência do acetato de glatirâmero
BR0307975A (pt) 2002-02-25 2005-01-11 Elan Pharm Inc Métodos para reduzir cronicamente a inflamação patológica em um paciente e para determinar a eficácia de um regime de administração crÈnica para tratar inflamação patológica em um indivìduo, composição e terapia combinada para tratamento crÈnico de inflamação patológica em um paciente e uso de um inibidor de alfa-4-integrina
SK50642005A3 (sk) * 2003-01-24 2006-02-02 Elan Pharmaceuticals, Inc. Kompozícia na liečenie demyelizačných ochorení a paralýzy podávaním remyelizačných látok
WO2006029411A2 (en) 2004-09-09 2006-03-16 Yeda Research And Development Co. Ltd. Mixtures of polypeptides, compositions containing and processes for preparing same, and uses thereof
CZ29723U1 (cs) 2009-08-20 2016-08-30 Yeda Research & Development Company, Ltd. Nízkofrekvenční terapie s glatiramer acetátem
USRE49251E1 (en) 2010-01-04 2022-10-18 Mapi Pharma Ltd. Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
US8759302B2 (en) 2010-03-16 2014-06-24 Teva Pharmaceutical Industries, Ltd. Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis
NZ609938A (en) 2010-10-11 2015-11-27 Teva Pharma Cytokine biomarkers as predictive biomarkers of clinical response for glatiramer acetate
CA2851510A1 (en) 2011-10-10 2013-04-18 Teva Pharmaceutical Industries Ltd. Single nucleotide polymorphisms useful to predict clinical response for glatiramer acetate
NZ630421A (en) 2012-10-10 2018-07-27 Teva Pharma Biomarkers predictive for clinical response for glatiramer acetate
UY35790A (es) 2013-10-21 2015-05-29 Teva Pharma Marcadores genéticos que predicen la respuesta al acetato de glatiramer
CN105884866B (zh) * 2015-01-26 2021-04-20 漳州未名博欣生物医药有限公司 格拉替雷的化学合成方法
US9155775B1 (en) 2015-01-28 2015-10-13 Teva Pharmaceutical Industries, Ltd. Process for manufacturing glatiramer acetate product
CN107531750B (zh) * 2015-04-28 2021-03-16 深圳翰宇药业股份有限公司 多肽混合物高效液相色谱分析方法
US11167003B2 (en) 2017-03-26 2021-11-09 Mapi Pharma Ltd. Methods for suppressing or alleviating primary or secondary progressive multiple sclerosis (PPMS or SPMS) using sustained release glatiramer depot systems
WO2019002228A1 (en) 2017-06-26 2019-01-03 Institut Pasteur TREATMENTS TO REMOVE HIV RESERVOIRS AND REDUCE VIRAL LOAD

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL113812A (en) * 1994-05-24 2000-06-29 Yeda Res & Dev Copolymer-1 pharmaceutical compositions containing it and its use
US5719296A (en) * 1995-10-30 1998-02-17 Merck & Co., Inc. Pseudopeptide lactam inhibitors of peptide binding to MHC class II proteins

Also Published As

Publication number Publication date
EA199900621A1 (ru) 2000-02-28
AU737287B2 (en) 2001-08-16
PL193300B1 (pl) 2007-01-31
JP4216342B2 (ja) 2009-01-28
JP2001511121A (ja) 2001-08-07
CZ243799A3 (cs) 2000-06-14
CN100528222C (zh) 2009-08-19
CN1249690A (zh) 2000-04-05
EP0975351B1 (en) 2007-03-14
CA2277365C (en) 2011-04-12
HUP0001917A3 (en) 2001-12-28
EP0975351A4 (en) 2002-05-15
HU226612B1 (en) 2009-04-28
IL119989A0 (en) 1997-04-15
AU5819598A (en) 1998-08-03
EP0975351A1 (en) 2000-02-02
ZA98214B (en) 1999-08-11
WO1998030227A1 (en) 1998-07-16
CA2277365A1 (en) 1998-07-16
CZ297983B6 (cs) 2007-05-16
EA003128B1 (ru) 2003-02-27
BR9807076B1 (pt) 2013-10-29
DE69837324T2 (de) 2007-11-29
HK1025737A1 (en) 2000-11-24
IL130820A (en) 2007-03-08
SK284029B6 (sk) 2004-08-03
NZ336690A (en) 2001-05-25
BR9807076A (pt) 2000-05-02
SK93199A3 (en) 2000-11-07
DE69837324D1 (de) 2007-04-26
KR20000070058A (ko) 2000-11-25
PL334566A1 (en) 2000-03-13
HUP0001917A2 (hu) 2000-10-28
ATE356608T1 (de) 2007-04-15

Similar Documents

Publication Publication Date Title
BRPI9807076B8 (pt) "uso de acetato de glatirâmero para a fabricação de medicamento para o tratamento de esclerose múltipla e composição farmacêutica"
HUP0101293A2 (hu) AspB28-humán inzulint tartalmazó inhalációs gyógyászati készítmény és alkalmazása
RU95110109A (ru) Комплекс, содержащий аналог человеческого инсулина, и фармацевтическая композиция на его основе
HUP0104255A2 (hu) Inhalációra alkalmas gyógyászati készítmény
IL113812A0 (en) Copolymer-1, pharmaceutical compositions containing it and its use
FI945912A0 (fi) Proteinoidikantajat ja menetelmät niiden valmistamiseksi sekä niiden käyttö
FR2651677B1 (fr) Composition pharmaceutique a base de salmeterol et du propionate de fluticasone.
ATE204178T1 (de) Methode zur behandlung und vorbeugung von typ-1 diabetis durch orale verabreichung von insulin
HK1030157A1 (en) Use of consensus interferon and compositions comprising consensus interferon.
AU5526899A (en) Bioactive peptides
OA09772A (en) "mometasone furoate monohydrate, process for making same and pharmaceutical compositions".
CA2124677A1 (en) Immunopotentiatory agents and physiologically acceptable salts thereof
ATE213499T1 (de) Peptidanaloge des menschlichen, basischen myelinproteins mit substitution an position 91 zur behandlung der multiplen sklerose
RU94037764A (ru) Фармацевтические бактериоциновые композиции и их применение
DE69033183T2 (de) Phosphozucker enthaltende pharmazeutische zubereitung
KR910002899A (ko) 혈조절 펩타이드
AU7683296A (en) Peptide conjugates derived from thymic hormones, their use as medicament and compositions containing them
WO1996022305A3 (en) Modified peptides
AU773079C (en) Immunopotentiating compositions
NZ332655A (en) Pharmaceutical compositions containing diclofenac and alkali metal bicarbonates
ATE56148T1 (de) Orales dextran enthaltende zusammensetzungen.
CA2279184A1 (en) Pharmaceutical compositions containing ibuprofen and domperidone for the treatment of migraine
GR1002576B (el) Φαρμακευτικες συνθεσεις και μια μεθοδος παρασκευης τους.
WO2000015797A3 (en) Compositions and methods for the treatment of immune related diseases
ATE223700T1 (de) Ramoplaninhaltige neue injizierbare arzneizubereitungen

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: DE ACORDO COM O ART. 37, INDEFIRO DO PRESENTE PEDIDO, UMA VEZ QUE NAO ATENDE AO REQUISITO DE ATIVIDADE INVENTIVA ( ART. 8O COMBINADO COM O ART. 13 DA LPI 9279/96).

B12B Appeal against refusal [chapter 12.2 patent gazette]
B07F Notification of approval that there is no relation to art. 229 of lpi (pipeline patents) [chapter 7.6 patent gazette]
B07B Technical examination (opinion): publication cancelled [chapter 7.2 patent gazette]

Free format text: DESPACHO: ANULADA A DECISAO DE NEGAR ANUENCIA AO PI ASSINALADO CUJA PUBLICACAO FOI EFETUADA NA RPI 2164 DE 26/06/2012. O PI 9807076-2 DEVERA RETORNAR PARA EXAME TECNICO DE PREVIA ANUENCIA. ESTA ANULACAO TEM COMO BASE A RESOLUCAO- RE NO. 3.255, DE 30/6/2012, PUBLICADA NO DOU EM 31/07/2012.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 29/10/2013, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 12/01/1998 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21A Patent or certificate of addition expired [chapter 21.1 patent gazette]

Free format text: PATENTE EXTINTA EM 12/01/2018

B15V Prolongation of time limit allowed